2013
DOI: 10.1016/j.ejmech.2013.10.034
|View full text |Cite
|
Sign up to set email alerts
|

Design, diversity-oriented synthesis and structure activity relationship studies of quinolinyl heterocycles as antimycobacterial agents

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
19
0

Year Published

2015
2015
2021
2021

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 33 publications
(19 citation statements)
references
References 28 publications
0
19
0
Order By: Relevance
“…According to the research by Encinas et al, benzofuran pyrazole derivatives showed considerable in vitro activity against MTB H37Rv, and compound 385 showed the most potency with MIC 90 of 0.05 µM [ 284 ]. A series of quinolinyl heterocycles were evaluated for their anti-mycobacterial activity against M. smegmatis , and some quinolinyl pyrazole hybrids showed excellent anti-mycobacterial activity such as 386 (MIC = 14.66 µg/mL) was as potent as isoniazide (MIC = 12.07 µg/mL) [ 285 ].The in vitro abilities of quinazolinone pyrazole derivatives to inhibit growth of MTB H37Rv have been reported by Pandit et al The results exhibited all hybrids showed considerable anti-TB activity, particularly, hybrid 387 (96%, MIC 90 < 3.125 µg/mL) warrant further investigation [ 286 ]. Dihydropyrimidine pyrazole derivatives were synthesized and evaluated for their in vitro anti-tubercular activity against MTB H37Rv, compound 388 were found to be the most active compounds in vitro with MIC of 0.02 µg/mL, with the highest SI > 500 were more potent than INH (0.03 µg/mL) [ 287 ].…”
Section: Pharmacological Activitiesmentioning
confidence: 99%
“…According to the research by Encinas et al, benzofuran pyrazole derivatives showed considerable in vitro activity against MTB H37Rv, and compound 385 showed the most potency with MIC 90 of 0.05 µM [ 284 ]. A series of quinolinyl heterocycles were evaluated for their anti-mycobacterial activity against M. smegmatis , and some quinolinyl pyrazole hybrids showed excellent anti-mycobacterial activity such as 386 (MIC = 14.66 µg/mL) was as potent as isoniazide (MIC = 12.07 µg/mL) [ 285 ].The in vitro abilities of quinazolinone pyrazole derivatives to inhibit growth of MTB H37Rv have been reported by Pandit et al The results exhibited all hybrids showed considerable anti-TB activity, particularly, hybrid 387 (96%, MIC 90 < 3.125 µg/mL) warrant further investigation [ 286 ]. Dihydropyrimidine pyrazole derivatives were synthesized and evaluated for their in vitro anti-tubercular activity against MTB H37Rv, compound 388 were found to be the most active compounds in vitro with MIC of 0.02 µg/mL, with the highest SI > 500 were more potent than INH (0.03 µg/mL) [ 287 ].…”
Section: Pharmacological Activitiesmentioning
confidence: 99%
“…[1][2][3][4][5][6][7] The production of these libraries allows for the analysis of structure-activity relationships of the compounds, which helps inform further development of probes with diverse activity. [8][9][10][11][12][13][14][15][16] Biological performance diversity can be defined as the ability of a compound library to target a broad variety of biological functions, while containing few molecules with redundant activity. Such libraries more efficiently use resources, due to a smaller library footprint, while potentially increasing hit rates.…”
Section: Introductionmentioning
confidence: 99%
“…Different coupling reagents are used for the final cyclization including DIC, DCC as carbodiimides, TBTU as uronium coupling reagent 46 . Considering these characteristics, IBD is one of the common coupling reagents and additives used in cyclization chemistry [47][48][49][50] . Considering these characteristics, IBD is one of the common coupling reagents and additives used in cyclization chemistry [47][48][49][50] .…”
Section: Cytotoxicity (Brine Shrimp Lethality Bioassay)mentioning
confidence: 99%